One World Cannabis, Ltd. (OTCQB:OWCP)Detailed Quote · Free Stock Analysis
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively “OWC” or the “Company”) conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
The Company’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
Dr. Yehuda Baruch served as Head of the Israeli Ministry of Health’s Medical Marijuana Program from 2003 through 2013 where he spearheaded the efforts on regulation, chaired the indication committee, secured Helsinki Approvals for medical research, and managed regulation of patient licensing and dosage. He has extensive experience in researching medical cannabis, most notably for its effect on PTSD.
Dr. Sharon Rozenblat, Advisory Board Member for OWC Pharmaceutical Research Corp., is largely responsible for the development of the company’s active cannabinoid topical cream designed to treat psoriasis.
Jeffrey Friedland is an emerging market pioneer — his firm, Friedland Global Capital, was one of the first American investment banks to establish a presence in China — and he can now be found on the forefront of the global cannabis industry. In his book, Marijuana, the World’s Most Misunderstood Plant, Mr. Friedland dives into the world of medical marijuana, discussing the plants history, what we know and what we still hope to discover.
- List of Medical Marijuana Stocks
- OWC Pharma’s Dr. Rozenblat Eyes Huge Potential for Psoriasis Cream
- OWC Pharmaceutical Research Corp. Announces Market Readiness of its Cannabinoid-based Topical Cream for Skin Conditions Starting With Psoriasis
- OWC Pharmaceuticals Engages CFN Media to Cultivate New Investor Audience & Communicate with Existing Shareholders
- Top 10 Medical Marijuana Stocks
Around the Web
- OWC Pharmaceutical Research Corporation to Present at the 2018 Wall St Conference
- OWC Pharmaceutical Research Corp. Announces Update on its Proprietary Medical Cannabis Sublingual Tablet
- OWC Pharma Issues Chairman’s Letter to Shareholders
- OWC Pharmaceutical Research Corp Appoints Dr. Stanley Hirsch as its Active Chairman
- CFN Media Exclusive Interview with OWCP’s Dr. Sharon Rozenblat
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
CannabisFN.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. CannabisFN.com received fees for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.
Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.